{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:21:26Z","timestamp":1787696486703,"version":"build-2784847793"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00520-021-06438-9","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T04:03:46Z","timestamp":1628913826000},"page":"8089-8096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-3993","authenticated-orcid":false,"given":"Mellar","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Capela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"DeFeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Del Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"6438_CR1","doi-asserted-by":"publisher","unstructured":"Huang X, Xue J, Gao M et al (2020) Medical management of inoperable malignant bowel obstruction. Ann Pharmacother. 55(9):1134\u20131145. https:\/\/doi.org\/10.1177\/1060028020979773","DOI":"10.1177\/1060028020979773"},{"issue":"8","key":"6438_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ejca.2008.02.028","volume":"44","author":"CI Ripamonti","year":"2008","unstructured":"Ripamonti CI, Easson AM, Gerdes H (2008) Management of malignant bowel obstruction. Eur J Cancer. 44(8):1105\u20131115","journal-title":"Eur J Cancer."},{"issue":"2","key":"6438_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1525-1438.2002.01103.x","volume":"12","author":"C Ripamonti","year":"2002","unstructured":"Ripamonti C, Bruera E (2002) Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 12(2):135\u2013143","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"6438_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3949\/ccjm.78a.10052","volume":"78","author":"A Soriano","year":"2011","unstructured":"Soriano A, Davis MP (2011) Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 78(3):197\u2013206","journal-title":"Cleve Clin J Med."},{"issue":"3","key":"6438_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1049909110361228","volume":"27","author":"SK Ang","year":"2010","unstructured":"Ang SK, Shoemaker LK, Davis MP (2010) Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 27(3):219\u2013225","journal-title":"Am J Hosp Palliat Care."},{"issue":"1","key":"6438_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0885-3924(94)90141-4","volume":"9","author":"RL Fainsinger","year":"1994","unstructured":"Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage. 9(1):12\u201318","journal-title":"J Pain Symptom Manage."},{"issue":"3","key":"6438_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.soc.2021.02.004","volume":"30","author":"J Bleicher","year":"2021","unstructured":"Bleicher J, Lambert LA (2021) A palliative approach to management of peritoneal carcinomatosis and malignant ascites. Surg Oncol Clin N Am. 30(3):475\u2013490","journal-title":"Surg Oncol Clin N Am."},{"issue":"4","key":"6438_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jpainsymman.2009.08.010","volume":"39","author":"MP Davis","year":"2010","unstructured":"Davis MP, Hallerberg G (2010) Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and\/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 39(4):756\u2013767","journal-title":"J Pain Symptom Manage."},{"issue":"1","key":"6438_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","volume":"25","author":"D Walsh","year":"2017","unstructured":"Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A (2017) 2016 Updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 25(1):333\u2013340","journal-title":"Support Care Cancer."},{"issue":"1","key":"6438_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.annonc.a058345","volume":"4","author":"C Ripamonti","year":"1993","unstructured":"Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ (1993) Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 4(1):15\u201321","journal-title":"Ann Oncol."},{"issue":"1","key":"6438_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/030089160108700101","volume":"87","author":"C Ripamonti","year":"2001","unstructured":"Ripamonti C, Panzeri C, Groff L, Galeazzi G, Boffi R (2001) The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori. 87(1):1\u20139","journal-title":"Tumori."},{"issue":"3","key":"6438_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s005200050283","volume":"8","author":"S Mercadante","year":"2000","unstructured":"Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 8(3):188\u2013191","journal-title":"Support Care Cancer."},{"issue":"1","key":"6438_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","volume":"19","author":"C Ripamonti","year":"2000","unstructured":"Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 19(1):23\u201334","journal-title":"J Pain Symptom Manage."},{"issue":"2","key":"6438_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jpainsymman.2006.06.014","volume":"33","author":"S Mercadante","year":"2007","unstructured":"Mercadante S, Casuccio A, Mangione S (2007) Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 33(2):217\u2013223","journal-title":"J Pain Symptom Manage."},{"issue":"5","key":"6438_CR15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0885-3924(98)00096-7","volume":"16","author":"S Mercadante","year":"1998","unstructured":"Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manage. 16(5):278\u2013280","journal-title":"J Pain Symptom Manage."},{"issue":"3","key":"6438_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/BF00368889","volume":"3","author":"S Mercadante","year":"1995","unstructured":"Mercadante S (1995) Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer. 3(3):190\u2013193","journal-title":"Support Care Cancer."},{"issue":"4","key":"6438_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/026921639300700406","volume":"7","author":"S Mercadante","year":"1993","unstructured":"Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT (1993) Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 7(4):295\u2013299","journal-title":"Palliat Med."},{"issue":"5","key":"6438_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jjco\/hyn035","volume":"38","author":"Y Shima","year":"2008","unstructured":"Shima Y, Ohtsu A, Shirao K, Sasaki Y (2008) Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 38(5):354\u2013359","journal-title":"Jpn J Clin Oncol."},{"issue":"9","key":"6438_CR19","first-page":"1377","volume":"31","author":"Y Shima","year":"2004","unstructured":"Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y (2004) A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient. Gan To Kagaku Ryoho. 31(9):1377\u20131382","journal-title":"Gan To Kagaku Ryoho."},{"issue":"8789","key":"6438_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0140-6736(92)91700-I","volume":"339","author":"D Khoo","year":"1992","unstructured":"Khoo D, Riley J, Waxman J (1992) Control of emesis in bowel obstruction in terminally ill patients. Lancet. 339(8789):375\u2013376","journal-title":"Lancet."},{"issue":"1","key":"6438_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1006\/gyno.1999.5406","volume":"74","author":"J Philip","year":"1999","unstructured":"Philip J, Lickiss N, Grant PT, Hacker NF (1999) Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol. 74(1):68\u201373","journal-title":"Gynecol Oncol."},{"issue":"3","key":"6438_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1006\/gyno.1996.0154","volume":"61","author":"G Mangili","year":"1996","unstructured":"Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A (1996) Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 61(3):345\u2013348","journal-title":"Gynecol Oncol."},{"issue":"4","key":"6438_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s005200000198","volume":"9","author":"C Ripamonti","year":"2001","unstructured":"Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, de Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P, Working Group of the European Association for Palliative Care (2001) Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 9(4):223\u2013233","journal-title":"Support Care Cancer."},{"issue":"8","key":"6438_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/0885-3924(91)90005-O","volume":"6","author":"F De Conno","year":"1991","unstructured":"De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 6(8):484\u2013486","journal-title":"J Pain Symptom Manage."},{"issue":"6","key":"6438_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jpainsymman.2016.05.032","volume":"52","author":"GP Obita","year":"2016","unstructured":"Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW (2016) Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manage. 52(6):901\u2013919 e901","journal-title":"J Pain Symptom Manage."},{"issue":"5","key":"6438_CR26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","volume":"49","author":"DC Currow","year":"2015","unstructured":"Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage. 49(5):814\u2013821","journal-title":"J Pain Symptom Manage."},{"issue":"35","key":"6438_CR27","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1200\/JCO.2011.40.5712","volume":"30","author":"P Mariani","year":"2012","unstructured":"Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 30(35):4337\u20134343","journal-title":"J Clin Oncol."},{"issue":"1","key":"6438_CR28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1186\/s12885-020-07549-y","volume":"20","author":"N McCaffrey","year":"2020","unstructured":"McCaffrey N, Asser T, Fazekas B, Muircroft W, Agar M, Clark K, Eckermann S, Lee J, Joshi R, Allcroft P, Sheehan C, Currow DC (2020) Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer. 20(1):1050","journal-title":"BMC Cancer."},{"issue":"12","key":"6438_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00520-009-0609-3","volume":"17","author":"K Clark","year":"2009","unstructured":"Clark K, Lam L, Currow D (2009) Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer. 17(12):1463\u20131468","journal-title":"Support Care Cancer."},{"issue":"9","key":"6438_CR30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1248\/yakushi.126.767","volume":"126","author":"H Itoh","year":"2006","unstructured":"Itoh H (2006) Clinicopharmacological study of gastrointestinal drugs from the viewpoint of postmarketing development. Yakugaku Zasshi. 126(9):767\u2013778","journal-title":"Yakugaku Zasshi."},{"key":"6438_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12957-015-0455-3","volume":"13","author":"X Peng","year":"2015","unstructured":"Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 13:50","journal-title":"World J Surg Oncol."},{"issue":"7","key":"6438_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/jpm.2020.0101","volume":"23","author":"K Kaneishi","year":"2020","unstructured":"Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, Kanai Y, Oyamada S, Yamaguchi T, Morita T, Iwase S (2020) Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med. 23(7):880\u2013881","journal-title":"J Palliat Med."},{"issue":"3 Suppl","key":"6438_CR33","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1136\/gut.35.3_Suppl.S11","volume":"35","author":"C Owyang","year":"1994","unstructured":"Owyang C (1994) Octreotide in gastrointestinal motility disorders. Gut. 35(3 Suppl):S11\u2013S14","journal-title":"Gut."},{"issue":"5","key":"6438_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/gut.36.5.755","volume":"36","author":"MF Stolk","year":"1995","unstructured":"Stolk MF, van Erpecum KJ, Koppeschaar HP, Samsom M, Smout AJ, Akkermans LM, Peeters TL, vanBerge-Henegouwen GP (1995) Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut. 36(5):755\u2013760","journal-title":"Gut."},{"issue":"1 Pt 1","key":"6438_CR35","first-page":"G4","volume":"272","author":"P Poitras","year":"1997","unstructured":"Poitras P, Trudel L, Miller P, Gu CM (1997) Regulation of motilin release: studies with ex vivo perfused canine jejunum. Am J Physiol. 272(1 Pt 1):G4\u2013G9","journal-title":"Am J Physiol."},{"issue":"5","key":"6438_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40272-016-0189-x","volume":"18","author":"L Ambartsumyan","year":"2016","unstructured":"Ambartsumyan L, Flores A, Nurko S, Rodriguez L (2016) Utility of octreotide in advancing enteral feeds in children with chronic intestinal pseudo-obstruction. Paediatr Drugs. 18(5):387\u2013392","journal-title":"Paediatr Drugs."},{"issue":"7","key":"6438_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/00365528809090758","volume":"23","author":"TL Peeters","year":"1988","unstructured":"Peeters TL, Romanski KW, Janssens J, Vantrappen G (1988) Effect of the long-acting somatostatin analogue SMS 201-995 on small-intestinal interdigestive motility in the dog. Scand J Gastroenterol. 23(7):769\u2013774","journal-title":"Scand J Gastroenterol."},{"issue":"8","key":"6438_CR38","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/gut.35.8.1064","volume":"35","author":"K Haruma","year":"1994","unstructured":"Haruma K, Wiste JA, Camilleri M (1994) Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut. 35(8):1064\u20131069","journal-title":"Gut."},{"issue":"6","key":"6438_CR39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1136\/gut.41.6.758","volume":"41","author":"MI van Berge Henegouwen","year":"1997","unstructured":"van Berge Henegouwen MI, van Gulik TM, Akkermans LM, Jansen JB, Gouma DJ (1997) The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut. 41(6):758\u2013762","journal-title":"Gut."},{"issue":"2","key":"6438_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1365-2036.1998.00289.x","volume":"12","author":"MC Edmunds","year":"1998","unstructured":"Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW (1998) Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 12(2):167\u2013174","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"6438_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0022-4804(90)90172-X","volume":"49","author":"WO Richards","year":"1990","unstructured":"Richards WO, Geer R, O\u2019Dorisio TM et al (1990) Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res. 49(6):483\u2013487","journal-title":"J Surg Res."},{"issue":"6","key":"6438_CR42","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/BF02093781","volume":"39","author":"JJ Cullen","year":"1994","unstructured":"Cullen JJ, Eagon JC, Kelly KA (1994) Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide. Dig Dis Sci. 39(6):1179\u20131184","journal-title":"Dig Dis Sci."},{"issue":"9155","key":"6438_CR43","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0140-6736(05)76666-6","volume":"353","author":"G Nordesjo-Haglund","year":"1999","unstructured":"Nordesjo-Haglund G, Lonnqvist B, Lindberg G, Hellstrom-Lindberg E (1999) Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation. Lancet. 353(9155):846","journal-title":"Lancet."},{"issue":"21","key":"6438_CR44","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","volume":"325","author":"HC Soudah","year":"1991","unstructured":"Soudah HC, Hasler WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 325(21):1461\u20131467","journal-title":"N Engl J Med."},{"issue":"3","key":"6438_CR45","first-page":"361","volume":"24","author":"T Lecomte","year":"2000","unstructured":"Lecomte T, Cavicchi M, Delchier JC (2000) Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol. 24(3):361\u2013363","journal-title":"Gastroenterol Clin Biol."},{"issue":"8","key":"6438_CR46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ejpain.2008.10.006","volume":"13","author":"AA Dahaba","year":"2009","unstructured":"Dahaba AA, Mueller G, Mattiassich G, Rumpold-Seitlinger G, Bornemann H, Rehak PH, Linck G, Mischinger HJ, Metzler H (2009) Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery. Eur J Pain. 13(8):861\u2013864","journal-title":"Eur J Pain."},{"issue":"1","key":"6438_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0002-9610(05)80413-1","volume":"165","author":"JJ Cullen","year":"1993","unstructured":"Cullen JJ, Eagon JC, Dozois EJ, Kelly KA (1993) Treatment of acute postoperative ileus with octreotide. Am J Surg. 165(1):113\u2013119 discussion 119-120","journal-title":"Am J Surg."},{"issue":"20","key":"6438_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020288","volume":"99","author":"Z Wu","year":"2020","unstructured":"Wu Z, Wang S, Yuan S, Lin M (2020) Clinical efficacy and safety of somatostatin in the treatment of early postoperative inflammatory small bowel obstruction: a protocol for systematic review and meta analysis. Medicine (Baltimore). 99(20):e20288","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"6438_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/cpt196896745","volume":"9","author":"JP Guignard","year":"1968","unstructured":"Guignard JP, Herxheimer A, Greenwood RM (1968) Effects of hyoscine butylbromide on gut motility. Clin Pharmacol Ther. 9(6):745\u2013748","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"6438_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2125.1977.tb00721.x","volume":"4","author":"A Herxheimer","year":"1977","unstructured":"Herxheimer A, de Groot AC (1977) Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology. Br J Clin Pharmacol. 4(3):337\u2013342","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"6438_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1476-5381.1958.tb00215.x","volume":"13","author":"A Herxheimer","year":"1958","unstructured":"Herxheimer A (1958) A comparison of some atropine-like drugs in man, with particular reference to their end-organ specificity. Br J Pharmacol Chemother. 13(2):184\u2013192","journal-title":"Br J Pharmacol Chemother."},{"issue":"5","key":"6438_CR52","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2165\/00003495-199244050-00003","volume":"44","author":"M Deakin","year":"1992","unstructured":"Deakin M, Williams JG (1992) Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Drugs. 44(5):709\u2013719","journal-title":"Drugs."},{"issue":"1","key":"6438_CR53","first-page":"7","volume":"16","author":"SJ Konturek","year":"1981","unstructured":"Konturek SJ, Radecki T, Brzozowski T, Piastucki I, Dembinska-Kiec A, Zmuda A (1981) Gastric cytoprotection by prostaglandins, ranitidine, and probanthine in rats. Role of endogenous prostaglandins. Scand J Gastroenterol. 16(1):7\u201312","journal-title":"Scand J Gastroenterol."},{"issue":"1","key":"6438_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0014-2999(89)90612-2","volume":"162","author":"S Katsoulis","year":"1989","unstructured":"Katsoulis S, Conlon JM (1989) Calcitonin gene-related peptides relax guinea pig and rat gastric smooth muscle. Eur J Pharmacol. 162(1):129\u2013134","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"6438_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/0016-5085(84)90711-X","volume":"87","author":"Y Tache","year":"1984","unstructured":"Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H (1984) Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 87(2):344\u2013349","journal-title":"Gastroenterology."},{"issue":"1 Pt 1","key":"6438_CR56","first-page":"G145","volume":"256","author":"P Bauerfeind","year":"1989","unstructured":"Bauerfeind P, Hof R, Hof A, Cucala M, Siegrist S, von Ritter C, Fischer JA, Blum AL (1989) Effects of hCGRP I and II on gastric blood flow and acid secretion in anesthetized rabbits. Am J Physiol. 256(1 Pt 1):G145\u2013G149","journal-title":"Am J Physiol."},{"issue":"11","key":"6438_CR57","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1211\/002235702117","volume":"54","author":"H Itoh","year":"2002","unstructured":"Itoh H, Naito T, Takeyama M (2002) Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 54(11):1559\u20131563","journal-title":"J Pharm Pharmacol."},{"issue":"3","key":"6438_CR58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1476-5381.1982.tb09316.x","volume":"77","author":"G Bertaccini","year":"1982","unstructured":"Bertaccini G, Scarpignato C (1982) Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol. 77(3):443\u2013448","journal-title":"Br J Pharmacol."},{"issue":"1","key":"6438_CR59","first-page":"152","volume":"264","author":"S Ueki","year":"1993","unstructured":"Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z (1993) Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 264(1):152\u2013157","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"6438_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0306-4522(91)90218-D","volume":"41","author":"P Geppetti","year":"1991","unstructured":"Geppetti P, Del Bianco E, Patacchini R, Santicioli P, Maggi CA, Tramontana M (1991) Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: mechanism of action and biological response. Neuroscience. 41(1):295\u2013301","journal-title":"Neuroscience."},{"issue":"3","key":"6438_CR61","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0016-5085(95)90376-3","volume":"109","author":"FD Manela","year":"1995","unstructured":"Manela FD, Ren J, Gao J, McGuigan JE, Harty RF (1995) Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 109(3):701\u2013706","journal-title":"Gastroenterology."},{"issue":"1","key":"6438_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10620-006-3094-2","volume":"51","author":"T Shimatani","year":"2006","unstructured":"Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, Morikawa N (2006) Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 51(1):114\u2013120","journal-title":"Dig Dis Sci."},{"issue":"2","key":"6438_CR63","first-page":"295","volume":"32","author":"HX Yang","year":"2007","unstructured":"Yang HX, Luo D, Zou YY (2007) Effect of ranitidine on the gastric acid, plasma endothelin, and calcitonin gene-related peptide in patients undergoing the brain operation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32(2):295\u2013298","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban."},{"issue":"4 Pt 1","key":"6438_CR64","first-page":"G732","volume":"262","author":"J Ren","year":"1992","unstructured":"Ren J, Young RL, Lassiter DC, Rings MC, Harty RF (1992) Calcitonin gene-related peptide: mechanisms of modulation of antral endocrine cells and cholinergic neurons. Am J Physiol. 262(4 Pt 1):G732\u2013G739","journal-title":"Am J Physiol."},{"issue":"2","key":"6438_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0167-0115(97)01039-2","volume":"73","author":"J Ren","year":"1998","unstructured":"Ren J, Dunn ST, Tang Y, Wang Y, Gao J, Brewer K, Harty RF (1998) Effects of calcitonin gene-related peptide on somatostatin and gastrin gene expression in rat antrum. Regul Pept. 73(2):75\u201382","journal-title":"Regul Pept."},{"issue":"1","key":"6438_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI116177","volume":"91","author":"AK Sandvik","year":"1993","unstructured":"Sandvik AK, Dimaline R, Forster ER, Evans D, Dockray GJ (1993) Differential control of somatostatin messenger RNA in rat gastric corpus and antrum. Role of acid, food, and capsaicin-sensitive afferent neurons. J Clin Invest. 91(1):244\u2013250","journal-title":"J Clin Invest."},{"key":"6438_CR67","volume":"2","author":"DJ Feuer","year":"2000","unstructured":"Feuer DJ, Broadley KE (2000) Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2:CD001219","journal-title":"Cochrane Database Syst Rev."},{"issue":"9","key":"6438_CR68","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1023\/A:1008361102808","volume":"10","author":"DJ Feuer","year":"1999","unstructured":"Feuer DJ, Broadley KE (1999) Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 10(9):1035\u20131041","journal-title":"Ann Oncol."}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06438-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06438-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06438-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:09:57Z","timestamp":1666768197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06438-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6438"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06438-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"NA","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David Hui grant from Helsinn.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}